54313-35-8

Upstream product

• 29973-91-9 4-benzyloxy-3-methoxyphenylacetic acid 
• 79-37-8 oxalyl dichloride 
• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 65340-85-4 benzyl 2-(4-(benzyloxy)-3-methoxyphenyl)acetate 
• 306-08-1 Homovanillic acid 

Downstream Products

• 3972-80-3 (4-benzyloxy-3-methoxy-phenyl)-acetic acid-(3,4-dimethoxy-phenethylamide) 
• 79831-91-7 N-(4-benzyloxy-3,5-dimethoxyphenethyl)-2-(4-benzyloxy-3-methoxyphenyl)acetamide 
• 79624-56-9 N-(4,5-bisbenzyloxy-3-methoxyphenethyl)-2-(4-benzyloxy-3-methoxyphenyl)acetamide 
• 112462-79-0 2-(4-Benzyloxy-3-methoxy-phenyl)-N-(4,5-dimethoxy-2-trimethylsilanylmethyl-phenyl)-acetamide 
• 192190-36-6 N-((S)-1-phenylethyl)-2-(4-benzyloxy-3-methoxyphenyl)acetamide 
• 592529-11-8 2-(4-benzyloxy-3-methoxy-phenyl)-1-{2-[2-(4-methylsulfanyl-phenyl)-2-oxo-ethyl]-pyrrolidin-1-yl}-ethanone 
• 4672-96-2 2-[4-(benzyloxy)-3-methoxyphenyl]-N-[3-(benzyloxy)-4-methoxyphenethyl]acetamide 
• 75236-17-8 2-amino-6-hydroxy-7-methoxy-1,2,3,4-tetrahydronaphthalene 
• 788110-09-8 2-benzylamino-6-hydroxy-7-methoxy-1,2,3,4-tetrahydronaphthalene 
• 3979-56-4 AP-123/40765213 
• 1422239-95-9 C₃₃H₃₃NO₄ 
• 806600-50-0 6-(benzyloxy)-1-[4-(benzyloxy)-3-methoxybenzyl]-7-methoxy-3,4-dihydroisoquinoline 
• 1253735-92-0 C₅₁H₄₆BrNO₈ 

Relevant academic research and scientific papers

Design, synthesis of a novel 4-O-methylsaucerneol analogue LXY7824 as potent HIF-1 inhibitor and anti-cancer agent

Hypoxia-inducible factor-1 (HIF-1), an important transcription factor for tumor survival, is an attractive target for anti-cancer treatment. Herein, we present the design and synthesis of LXY7824, a simplified analogue of 4-O-methylsaucerneol. In addition

Designing new analogs for streamlining the structure of cytotoxic lamellarin natural products

Despite the therapeutic potential of marine-derived lamellarin natural products, their preclinical development has been hampered by their lipophilic nature, causing very poor aqueous solubility. In order to develop more drug-like analogs, their structure was streamlined in this study from both the cytotoxic activity and lipophilicity standpoints. First, a modified total synthetic route was successfully devised to construct a library of 59 systematically designed lamellarin analogs, which were then subjected to cytotoxicity and log P determinations. Along with the 25 first-generation lamellarins previously synthesized in our laboratory, the structure-activity and structure-lipophilicity relationships were extensively evaluated. Our results clearly indicated the additional structural requirements around the lamellarin skeleton which, when combined with those reported previously, can provide invaluable guidance for further modifications to increase the aqueous solubility of these compounds.

Facile and Divergent Synthesis of Lamellarins and Lactam-Containing Derivatives with Improved Drug Likeness and Biological Activities

With the goal to improve the aqueous solubility of lamellarins, the lactone ring in their skeleton was replaced with a lactam moiety in azalamellarins. However, the reported synthetic route produced such derivatives in very low yields. Hence, this study focused on developing an efficient simplified total synthetic scheme that could furnish both azalamellarins and the parent lamellarins from the same pyrrole ester intermediates. Subsequent comparative profiling revealed that the introduced lactone-to-lactam replacement rendered these molecules less lipophilic, whereas their cancer cytotoxicity remained equipotent to that of the parent compounds. Interestingly, their inhibitory activity was significantly enhanced towards the multifaceted GSK-3β enzyme. Our results clearly demonstrate the therapeutic potential of this promising class of marine-derived natural products and justify their further development, especially into anticancer agents.

TETRAHYDROPROTOBERBINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND NEURODEGENERATIVE DISEASES

Tetrahydroprotoberbine (THPB) compounds and their use in the treatment of neurological, psychiatric and neurodegenerative diseases is provided. The compounds include d-govadine, l-govadine and racemic govadine, as well as d-THPBs of general formula (I). Enantioselective processes for preparing compounds of formula (I), and d- and l-govadine are also provided.(I)

First enantioselective syntheses of the dopamine D1 and D2 receptor modulators, (+)-and (-)-govadine

There is a pressing need to find and develop new antipsychotic agents for the treatment of schizophrenia. Current drugs primarily target dopamine D2receptors and are only effective in the treatment of the positive symptoms of this indication. The tetrahyd

Substituted Isoquinolinones and Quinazolinones

The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.

Biosynthesis. Part 27.1,2 Colchicine: Studies of the phenolic oxidative coupling and ring-expansion processes based on incorporation of multiply labelled 1-phenethylisoquinolines

Earlier research from our group had proved that the biosynthesis of colchicine and its tropolonoid relatives involves the oxidative ring-closure of a 1-phenethyltetrahydroisoquinoline, autumnaline, followed by extensive modification of the cyclised product. These steps pose many mechanistic and stereochemical questions which are set out in the Introduction. The sequel then provides the answers based on the results from a series of incorporation experiments on Colchicum plants involving multiply labelled forms of autumnaline and its biological precursors. These multiply labelled samples required the synthesis of eleven differently labelled tetrahydroisoquinolines; the methods used to introduce the labels are described. Autumnaline is shown to be present in Colchicum autumnale plants and labelled forms of some precursors of it are synthesised and studied. Taken together, the findings allow further definition of a substantial part of the biosynthetic pathway to colchicine and its relatives.

Asymmetric synthesis of ( S)-l-(5-hydroxy-2-methoxybenzyl)-7-hydroxy-6-methoxy-2-methyl-1,2,3,4- tetrahydroisoquinoline (so-called "dehassiline")

Optically active, (S)-l-(5-hydroxy-2methoxybenzyl )-7-h.ydroxy-6-methoxy-2-meth.yl-l ,2,3,4tetrahydroisoquinoline (so-called "dehassiline") (1) was synthesized via highly stereoselective reduction of the 3,4-dihydroisoquinolinium ion possessing a chiral a

TETRACYCLIC SPIROBENZAZEPINE DOPAMINE ANTAGONISTS

Novel tetracyclic spirobenzazepine compounds of the formula STR1 or a pharmaceutically-acceptable salt, amide or ester thereof, which are dopamine D-1 receptor antagonists useful for treating dopamine-related neurological and psychological disorders, cogn